• 作者：Gisela Galindo Ortego^a ; ^b ; ^{ggalindo.lleida.ics@gencat.cat} ; Iné ; s Cruz Esteve^a ; ^b ; Jordi Real Gatius^b ; Leonardo Galvá ; n Santiago^c ; Carmen Monsó ; Lacruz^d ; Plá ; cido Santafé ; Soler^e
• 关键词：Insuficiencia card&iacute ; aca ; Polifarmacia ; Epidemiolog&iacute ; a ; Diferencias de g&eacute ; nero ; Atenci&oacute ; n primaria
• 刊名：Atenci贸n Primaria
• 出版年：2011
• 期刊代码：pca69_02126567
• 类别：med
• 出版时间：February 2011
• 卷：43
• 期：2
• 页码：61-67
• 文件大小：163 K

class="h4">Objective

To assess heart failure prevalence, epidemiology, co-morbidities and polypharmacy in our region from electronic patient records. To evaluate gender differences in heart failure patients.

class="h4">Design

Descriptive, cross-sectional study.

class="h4">Setting

Primary care Lleida (Spain).

class="h4">Participants

All patients from 21 primary care centers with the diagnosis of heart failure in medical records were included.

class="h4">Main outcome measurements

Demografic data, comorbidities and therapeutical subgroups in patients with a diagnosis of heart failure in their clinical record.

class="h4">Results

Heart failure was found in 0.99%(3017 from 306229 patients), of whom 59%were women, and a mean age of 80 years. Comorbidities: hypertension 67%, diabetes 30%, hyperlipidemia 26.5%, obesity 27%, ischemic heart disease 19%, stroke 11%, atrial fibrillation 31%, COPD 26%, renal failure 12%. Hypertension, hyperlipidemia and obesity were more frequent in women, COPD, ischemic heart disease and renal failure in men. There were no differences in diabetes, stroke and atrial fibrillation. Patients were prescribed a median of 8 different therapeutic subgroups (P25 = 6 and P75 = 11). Women were more frequently prescribed diuretics (76%), cardiac glycosides (22%) and ACE inhibitors/angiotensin II receptor antagonists, and men ACE inhibitors/angiotensin II receptor antagonists in combination with beta-blockers.

class="h4">Conclusions

Heart failure patients in primary care are elderly, with significant co-morbidities and treated with a high number of drugs. Gender differences exist in cardiovascular risk factors, co-morbidities, and also in therapy.